Re-evaluating duration of therapy in advanced non-small-cell lung cancer: Is it really duration or is it more about timing and exposure?

Journal of Clinical Oncology

Volumn 27, Issue 20, 2009, Pages 3268-3270

  Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; PLATINUM DERIVATIVE; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG EXPOSURE; EDITORIAL; EVALUATION; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; LUNG TUMOR; META ANALYSIS; MORTALITY; NOTE; PAIN; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SURVIVAL RATE; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 70249087714     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.4345     Document Type: Editorial

References (11)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials: Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995
2. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
3. Pirker R, Szczesna A, von Pawel J, et al: FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26:6s, 2008 (suppl; abstr 3)
4. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
5. Socinski MA, Stinchcombe TE: Duration of first-line chemotherapy in advanced non small-cell lung cancer: Less is more in the era of effective subsequent therapies. J Clin Oncol 25:5155-5157, 2007
6. Stinchcombe TE, Socinski MA: Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 4:243-250, 2009
7. Soon Y, Stockler MR, Askie L, et al: Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 27:3277-3283, 2009
8. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598, 2009
9. Ciuleanu TE, Brodowicz T, Belani CP, et al: Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 26:426s, 2008 (suppl; abstr 8011)
10. Pazdur R: Endpoints for assessing drug activity in clinical trials. Oncologist 13:19-21, 2008 (suppl 2)
11. Dancey JE, Dodd LE, Ford R, et al: Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer 45:281-289, 2009